Viewing data from:

ALVAIZ

NDA

ELTROMBOPAG CHOLINE | N216774 | TEVA PHARMACEUTICALS INC

4 strengths1 unique patent0 unique exclusivities

Patent Timeline

1 unique patent by expiration date

Active (1)Today

2027

2028

2029

2030

2031

2032

2033

2034

2035

2036

2037

2038

2039

Today

11072586

Nov. 5, 2038

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

VA Federal Supply Schedule

Government-negotiated contract prices | 8 NDCs (4 FSS, 4 Big4)

Lowest Price

$5131.30

Highest Price

$18405.92

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00480-3273-56ALVAIZ 9MG TAB	$5140.03	Big4	Teva Pharmaceuticals USA, Inc.	04/30/2026
00480-3273-56ALVAIZ 9MG TAB	$6780.52	FSS	Teva Pharmaceuticals USA, Inc.	04/30/2026
00480-3274-56ALVAIZ 18MG TAB	$5131.30	Big4	Teva Pharmaceuticals USA, Inc.	04/30/2026
00480-3274-56ALVAIZ 18MG TAB	$6780.52	FSS	Teva Pharmaceuticals USA, Inc.	04/30/2026
00480-3275-56ALVAIZ 36MG TAB	$9262.78	Big4	Teva Pharmaceuticals USA, Inc.	04/30/2026
00480-3275-56ALVAIZ 36MG TAB	$12270.60	FSS	Teva Pharmaceuticals USA, Inc.	04/30/2026
00480-3276-56ALVAIZ 54MG TAB	$13933.87	Big4	Teva Pharmaceuticals USA, Inc.	04/30/2026
00480-3276-56ALVAIZ 54MG TAB	$18405.92	FSS	Teva Pharmaceuticals USA, Inc.	04/30/2026

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Alvaiz (2024)

Total Spending

$8.2M

Total Claims

1,372

Beneficiaries

247

Avg Cost/Unit

$175.05

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

API Supply Chain1 active DMF

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

TAPI NL BVELTROMBOPAG CHOLINE

DMF 355202021

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Jan 20, 2026	SUPPL -6	View Letter (PDF)
Nov 29, 2023	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (4)

Sort:

#001 — EQ 9MG BASE

RLD

3 patents0 exclusivities▴

TABLET;ORAL | Approved: Nov 29, 2023

Patents (3)

Patent #	Expiration	PED	Drug Substance	Drug Product	Delist
11072586	Nov 5, 2038	—	Yes	Yes	—
11072586	Nov 5, 2038	—	Yes	Yes	—
11072586	Nov 5, 2038	—	Yes	Yes	—

#002 — EQ 18MG BASE

RLD

3 patents0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2023

#003 — EQ 36MG BASE

RLD

3 patents0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2023

#004 — EQ 54MG BASE

RLD

3 patents0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2023